Targets › PIM3
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. (UniProt, Q86V86)
Open in Phaseline: the race on PIM3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ryvu Therapeutics | MEN1703 (SEL24, Dapolsertib hydrochloride) Dual inhibitor of PIM kinases and FLT3 | PIM1, PIM2, PIM3, FLT3 | Phase 2 | Non-Hodgkin Lymphoma, B-cell | Dec 2026 |
| Sumitomo Pharma America | Nuvisertib (TP-3654) PIM kinase inhibitor | PIM1, PIM2, PIM3 | Phase 1 | Myelofibrosis | Apr 2027 |
Non-Hodgkin Lymphoma, B-cell (1) Myelofibrosis (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.